« | トップページ | »

2015年1月22日 (木)

参考になる表現が多いので、

下記の英文を加工して、

イートモに収録しようかな

An estimated 350 million carriers of hepatitis B virus suffer from a wide spectrum of clinical illnesses, and it has been suggested that the virus accounts for approximately 1 million deaths per year from hepatocellular carcinoma. The current standard of therapy for chronic hepatitis B e antigen (HBeAg)-positive infection is interferon-alpha. However, its efficacy, based on seroconversion, is only 30 percent. In this randomized, placebo-controlled, multicenter study, researchers evaluated the efficacy of 12 months of famciclovir (FAM) therapy in 417 HBeAg-positive patients. FAM is a nucleoside analog that has been licensed for the treatment of varicella zoster and herpes simplex suppression.Patients received FAM (500 mg 3 times daily or 1.5 g once daily) or placebo; 78 percent completed treatment and follow-up periods. All patients had detectable HBV DNA. Median HBV DNA levels declined by more than 70 percent within the first month in all FAM-treated patients. By the end of the 12-month treatment period, median decreases in HBV DNA from baseline were 76 percent in the 500-mg-FAM group and 60 percent in the 1.5-g-FAM group versus 37 percent in the placebo group; 13 percent to 14 percent of patients in each of the 3 groups had undetectable DNA at the end of the treatment. DNA levels rebounded to within 10 percent of baseline values in all patients when FAM was discontinued. Median histological activity index (HAI) scores on paired liver biopsy specimens were -1.5 in the 500-mg-FAM group and -1.0 in the 1.5-g-FAM group versus no change in the placebo group. The change in HAI scores between the 2 FAM groups was not statistically significant. The proportion of patients who converted to HBeAg-negative status and who had undetectable HBV DNA levels by the end of treatment was similar for the 3 groups. However, by the end of the 6-month follow-up period, patients who had received the 500-mg-FAM dose were more likely to exhibit sustained responses (P=0.052). FAM was tolerated well, and no cases of virologic resistance were noted.

« | トップページ | »

コメント

コメントを書く

(ウェブ上には掲載しません)

« | トップページ | »

各種リンク

サイト内検索
ココログ最強検索 by 暴想

アンケート